Metachromatic leukodystrophy (MLD) is a rare genetic disorder caused by mutations in the Arylsulfatase-A (ARSA) gene. The enzyme plays a key role in sulfatide metabolism in brain cells, and its deficiency leads to neurodegeneration. The clinical manifestations of MLD include stagnation and decline of motor and cognitive function, leading to premature death with limited standard treatment options. Here, we describe a mutation-agnostic hematopoietic stem and progenitor cell (HSPC) gene therapy using CRISPR-Cas9 and AAV6 repair template as a prospective treatment option for MLD. Our strategy achieved efficient insertions and deletions (>87%) and a high level of gene integration (>47%) at the ARSA locus in human bone marrow–derived HSPCs, with no detectable off-target editing. As a proof of concept, we tested our mutation-agnostic therapy in HSPCs derived from two MLD patients with distinct mutations and demonstrated restoration of ARSA enzyme activity (>30-fold improvement) equivalent to healthy adults. In summary, our investigation enabled a mutation-agnostic therapy for MLD patients with proven efficacy and strong potential for clinical translation.
Get full access to this article
View all access options for this article.
References
1.
van RappardDF, BoelensJJ, WolfNI. Metachromatic leukodystrophy: disease spectrum and approaches for treatment. Best Pract Res Clin Endocrinol Metab, 2015; 29:261–273. DOI: 10.1016/j.beem.2014.10.001.
2.
KehrerC, ElgunS, RaabeC, et al.Association of age at onset and first symptoms with disease progression in patients with metachromatic leukodystrophy. Neurology, 2021; 96:e255–e266. DOI: 10.1212/WNL.0000000000011047.
3.
Gieselmann VolkmarIK. Metachromatic Leukodystrophy. New York: McGraw-Hill, 2014.
4.
van der KnaapMS, BugianiM. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol, 2017; 134:351–382. DOI: 10.1007/s00401-017-1739-1.
5.
ShaimardanovaAA, ChulpanovaDS, SolovyevaVV, et al.Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches. Front Med (Lausanne), 2020; 7:576221. DOI: 10.3389/fmed.2020.576221.
6.
PiersonTM, BonnemannCG, FinkelRS, et al.Umbilical cord blood transplantation for juvenile metachromatic leukodystrophy. Ann Neurol, 2008; 64:583–587. DOI: 10.1002/ana.21522.
7.
BayeverE, LadischS, PhilippartM, et al.Bone-marrow transplantation for metachromatic leucodystrophy. Lancet, 1985; 2:471–473.
8.
KrivitW, ShapiroE, KennedyW, et al.Treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation. New Engl J Med, 1990; 322:28–32.
9.
DaliCÍ, SevinC, Krägeloh-MannI, et al.Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: results from a phase 1/2 clinical trial. Mol Genet Metab, 2020; 131:235–244. DOI: 10.1016/j.ymgme.2020.07.002.
10.
DaliCÍ, GroeschelS, MoldovanM, et al.Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study. Ann Clin Transl Neurol, 2021; 8:66–80. DOI: 10.1002/acn3.51254.
BoucherAA, MillerW, ShanleyR, et al.Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis, 2015; 10:94. DOI: 10.1186/s13023-015-0313-y.
13.
GroeschelS, KühlJ-S, BleyAE, et al.Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy compared with nontransplanted control patients. JAMA Neurol, 2016; 73:1133–1140. DOI: 10.1001/jamaneurol.2016.2067.
14.
Daniel-MorenoA, Lamsfus-CalleA, RajuJ, et al.CRISPR/Cas9-modified hematopoietic stem cells-present and future perspectives for stem cell transplantation. Bone Marrow Transplant, 2019; 54:1940–1950. DOI: 10.1038/s41409-019-0510-8.
15.
BiffiA, CapotondoA, FasanoS, et al.Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest, 2006; 116:3070–3082.
SessaM, LorioliL, FumagalliF, et al.Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet, 2016; 388:476–487. DOI: 10.1016/S0140-6736(16)30374-9.
18.
TucciF, ScaramuzzaS, AiutiA, et al.Update on clinical ex vivo hematopoietic stem cell gene therapy for inherited monogenic diseases. Mol Ther, 2021; 29:489–504. DOI: 10.1016/j.ymthe.2020.11.020.
19.
BiffiA, BartolomaeCC, CesanaD, et al.Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood, 2011; 117:5332–5339. DOI: 10.1182/blood-2010-09-306761.
20.
BraunCJ, BoztugK, ParuzynskiA, et al.Gene therapy for Wiskott–Aldrich syndrome—long-term efficacy and genotoxicity. Sci Transl Med, 2014; 6:227ra233. DOI: 10.1126/scitranslmed.3007280.
21.
Hacein-Bey-AbinaS, Von KalleC, SchmidtM, et al.LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 2003; 302:415–419.
22.
OttMG, SchmidtM, SchwarzwaelderK, et al.Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med, 2006; 12:401–409.
23.
AntonyJS, HaqueAKMA, Lamsfus-CalleA, et al.CRISPR/Cas9 system: a promising technology for the treatment of inherited and neoplastic hematological diseases. Adv Cell Gene Ther, 2018; 1:e10. DOI: https://doi.org/10.1002/acg2.10.
24.
EyquemJ, Mansilla-SotoJ, GiavridisT, et al.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature, 2017; 543:113–117. DOI: 10.1038/nature21405.
25.
Ureña-BailénG, Lamsfus-CalleA, Daniel-MorenoA, et al.CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies. Brief Funct Genomics, 2020; 19:191–200. DOI: 10.1093/bfgp/elz039.
26.
Lamsfus-CalleA, Daniel-MorenoA, Ureña-BailénG, et al.Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches. Blood Rev, 2020; 40:100641. DOI: 10.1016/j.blre.2019.100641.
27.
BöhringerJ, SanterR, SchumacherN, et al.Enzymatic characterization of novel arylsulfatase A variants using human arylsulfatase A-deficient immortalized mesenchymal stromal cells. Hum Mutat, 2017; 38:1511–1520. DOI: 10.1002/humu.23306.
28.
GuptaD, ShahHP, MaluK, et al.Differentiation and characterization of myeloid cells. Curr Protoc Immunol, 2014; 104:22F.5.1–22F.5.8. DOI: 10.1002/0471142735.im22f05s104.
29.
JohnsonRL, MilenkovicL, ScottMP. In vivo functions of the patched protein: requirement of the C terminus for target gene inactivation but not hedgehog sequestration. Mol Cell, 2000; 6:467–478. DOI: https://doi.org/10.1016/S1097-2765(00)00045-9.
30.
StrobelS, HesseN, SanthanakumaranV, et al.Optimization of enzyme essays to enhance reliability of activity measurements in leukocyte lysates for the diagnosis of metachromatic leukodystrophy and gangliosidoses. Cells, 2020; 9. DOI: 10.3390/cells9122553.
31.
TsaiSQ, ZhengZ, NguyenNT, et al.GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol, 2015; 33:187–197. DOI: 10.1038/nbt.3117.
32.
LiH. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. 2013;arXiv:1303.3997.
33.
TsaiSQ, TopkarVV, JoungJK, et al.Open-source guideseq software for analysis of GUIDE-seq data. Nat Biotechnol, 2016; 34:483–483. DOI: 10.1038/nbt.3534.
34.
QuinlanAR, HallIM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics, 2010; 26:841–842. DOI: 10.1093/bioinformatics/btq033.
35.
FrangoulH, AltshulerD, CappelliniMD, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New Engl J Med, 2021; 384:252–260. DOI: 10.1056/NEJMoa2031054.
36.
Lamsfus-CalleA, Daniel-MorenoA, AntonyJS, et al.Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34 HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin. Sci Rep, 2020; 10:10133. DOI: 10.1038/s41598-020-66309-x.
37.
RaiR, RomitoM, RiversE, et al.Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott–Aldrich syndrome. Nat Commun, 2020; 11:4034. DOI: 10.1038/s41467-020-17626-2.
38.
GoodwinM, LeeE, LakshmananU, et al.CRISPR-based gene editing enables gene repair in IPEX patient cells. Sci Adv, 2020; 6:eaaz0571. DOI: 10.1126/sciadv.aaz0571.
39.
AntonyJS, LatifiN, HaqueAKMA, et al.Gene correction of HBB mutations in CD34 hematopoietic stem cells using Cas9 mRNA and ssODN donors. Mol Cell Pediatr, 2018; 5:9. DOI: 10.1186/s40348-018-0086-1.
40.
FathS, BauerAP, LissM, et al.Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS One, 2011; 6:e17596. DOI: 10.1371/journal.pone.0017596.
41.
TranNT, GrafR, Wulf-GoldenbergA, et al.CRISPR-Cas9-mediated ELANE mutation correction in hematopoietic stem and progenitor cells to treat severe congenital neutropenia. Mol Ther, 2020; 28:2621–2634. DOI: 10.1016/j.ymthe.2020.08.004.
42.
Pavel-DinuM, WiebkingV, DejeneBT, et al.Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat Commun, 2019; 10:1634. DOI: 10.1038/s41467-019-09614-y.
43.
VerderaHC, KurandaK, MingozziF. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther, 2020; 28:723–746. DOI: 10.1016/j.ymthe.2019.12.010.
44.
SchiroliG, ContiA, FerrariS, et al.Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell, 2019; 24. DOI: 10.1016/j.stem.2019.02.019.
45.
RoccaCJ, RainaldiJN, SharmaJ, et al.CRISPR-Cas9 gene editing of hematopoietic stem cells from patients with Friedreich's ataxia. Mol Ther Methods Clin Dev, 2020; 17:1026–1036. DOI: 10.1016/j.omtm.2020.04.018.
46.
KleinstiverBP, PattanayakV, PrewMS, et al.High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature, 2016; 529:490–495. DOI: 10.1038/nature16526.
47.
ChenX, GillD, ShawP, et al.Outcome of early juvenile onset metachromatic leukodystrophy after unrelated cord blood transplantation: a case series and review of the literature. J Child Neurol, 2016; 31:338–344. DOI: 10.1177/0883073815595078.
48.
MernDS, ThoméC. Identification and characterization of human nucleus pulposus cell specific serotypes of adeno-associated virus for gene therapeutic approaches of intervertebral disc disorders. BMC Musculoskelet Disord, 2015; 16:341. DOI: 10.1186/s12891-015-0799-4.
49.
Lamsfus-CalleA, Daniel-MorenoA, Ureña-BailénG, et al.Universal gene correction approaches for β-hemoglobinopathies using CRISPR-Cas9 and adeno-associated virus serotype 6 donor templates. CRISPR J, 2021; 4:207–222. DOI: 10.1089/crispr.2020.0141.
50.
ShapiroJ, IancuO, JacobiAM, et al.Increasing CRISPR efficiency and measuring Its specificity in HSPCs using a clinically relevant system. Mol Ther Methods Clin Dev, 2020; 17:1097–1107. DOI: 10.1016/j.omtm.2020.04.027.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
